Scientists at Wake Forest School of Medicine have identified a dead probiotic that reduces age-related leaky gut in older mice. The study is published in the journal GeroScience.
But what exactly is leaky gut and what does a probiotic – dead or alive – have to do with it?
Some research has indicated that leaky gut, in which microbes and bacteria in the gut leak into the blood stream through holes or cracks in the intestinal lining, causes an increase in low-grade inflammation, and these conditions are common in older people. This resulting inflammation is thought to play a role in the development of many age-related diseases, such as diabetes, obesity, cancer, cardiovascular disease and decline in physical and cognitive functions.
“We know that probiotics are instrumental in maintaining a healthy gut and preventing leakage, but there isn’t much data available to pinpoint which ones work and which ones don’t,” said Hariom Yadav, Ph.D., assistant professor of molecular biology at Wake Forest School of Medicine and principal investigator of the study.
“Determining the strain that is most effective at reducing leaky gut and inflammation would help us target more effective strategies to address the problem, and help explain why probiotics work for some people but not others.”
In the study, Yadav’s team first screened eight strains of human-origin probiotics in roundworms, a commonly used model with a short lifespan of 11 to 20 days. They discovered that a strain of Lactobacillus paracasei (D3-5), even in the non-viable or heat-killed form, extended the roundworms’ life span.
They then tested their initial findings in mice. The results showed that feeding heat-killed D3-5 to older mice prevented high fat diet-induced metabolic dysfunctions, decreased leaky gut and inflammation, and improved physical and cognitive functions.
“Not only did we determine which probiotic strain was the most effective in preventing leaky gut and inflammation, we also showed that the dead version of that probiotic had the same benefits,” Yadav said. “This is the first-of-its kind study to show that a component (lipoteichoic acid) from the cell wall of a dead probiotic induced changes in the gut microbiome and mucin production, thereby reducing leaky gut and inflammation in elderly mice.
“We think our findings could be very useful to the food and supplement industries because dead probiotics have the potential to be more stable and have a longer shelf life than live probiotics.”
Yadav has filed a provisional patent application for D3-5.
Support for the study was provided by Wake Forest School of Medicine, National Institute of Diabetes and Digestive and Kidney Diseases, the National Heart, Lung, and Blood Institute, the National Institute on Aging and the Department of Defense.
Media Contact:
Marguerite Beck, marbeck@wakehealth.edu, 336-716-2415